DS
REGN icon

DRW Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

DRW Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-528
Closed -$405K – 1386
2026
Q1 		$405K Sell
528
-64
-11% -$49K 0.01% 723
2025
Q4 		$450K Buy
+592
New +$402K 0.01% 494
2025
Q3 		– Sell
-440
Closed -$231K – 1572
2025
Q2 		$231K Buy
+440
New +$246K 0.01% 883
2024
Q4 		– Sell
-228
Closed -$240K – 749
2024
Q3 		$240K Sell
228
-1
-0.4% -$1.11K 0.01% 482
2024
Q2 		$241K Sell
229
-589
-72% -$571K 0.01% 442
2024
Q1 		$766K Buy
+818
New +$778K 0.02% 200
2023
Q4 		– Sell
-477
Closed -$393K – 428
2023
Q3 		$393K Buy
+477
New +$375K 0.01% 243
2022
Q2 		– Sell
-397
Closed -$277K – 336
2022
Q1 		$277K Buy
+397
New +$251K 0.01% 218
2021
Q3 		– Sell
-567
Closed -$317K – 357
2021
Q2 		$317K Buy
+567
New +$287K 0.01% 221
2020
Q2 		– Sell
-520
Closed -$254K – 304
2020
Q1 		$254K Buy
+520
New +$214K 0.01% 226
2018
Q1 		– Sell
-1,080
Closed -$406K – 424
2017
Q4 		$406K Buy
+1,080
New +$437K 0.04% 254

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DRW Securities's REGN Position: Q2 2026 in Review

DRW Securities sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 528 shares — an estimated $405K sold.

DRW Securities first reported a position in REGN in Q4 2017 and held it in 11 quarters. The position peaked at $766K in Q1 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • DRW Securities reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 528 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $405K.
  • DRW Securities first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • DRW Securities's Regeneron Pharmaceuticals position peaked at $766K in Q1 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.